A dominant-negative mutant of c-Jun inhibits cell cycle progression during the transition of CD4(-)CD8(-) to CD4(+)CD8(+) thymocytes.

Important note: Information in this article was accurate in 1999. The state of the art may have changed since the publication date.

A dominant-negative mutant of c-Jun inhibits cell cycle progression during the transition of CD4(-)CD8(-) to CD4(+)CD8(+) thymocytes.

Int Immunol. 1999 Aug;11(8):1203-16. Unique Identifier : AIDSLINE MED/99352251
King LB; Tolosa E; Lenczowski JM; Lu F; Lind EF; Hunziker R; Petrie HT; Ashwell JD; Laboratory of Immune Cell Biology, National Cancer Institute,; National Institutes of Health, Bethesda MD 20892, USA.

Abstract: While Jun/Fos-containing transcription factors are known to be necessary for many TCR-mediated events in mature T cells, relatively little is known about their roles in thymocyte development. We have generated transgenic mice that express a trans-dominant-negative mutant of c-Jun (TAM-67) specifically in thymocytes. Expression of TAM-67 inhibited the up-regulation of AP-1-responsive genes such as c-jun and IL-2 in stimulated thymocytes from transgenic mice. In addition, altered thymocyte development in TAM-67-expressing mice was revealed by a decrease in thymic cellularity ( approximately 50%) which could be accounted for primarily by a reduction in the number of CD4(+)CD8(+) thymocytes, a large percentage of which retained CD25. The decrease in the number of CD4(+)CD8(+) thymocytes did not appear to be due to an enhanced rate of apoptosis but rather to a decrease in the number of CD4(-)CD8(-)CD25(-) cells in the S + G(2)/M stages of the cell cycle. These results indicate that Jun/Fos-containing transcription factors promote the proliferative burst that accompanies the transition from the CD4(-)CD8(-) to the CD4(+)CD8(+) stage of thymocyte development.

Keywords: JOURNAL ARTICLE Animal Cell Cycle Cell Differentiation CD4-Positive T-Lymphocytes/*CYTOLOGY CD8-Positive T-Lymphocytes/*CYTOLOGY Gene Expression Regulation, Developmental *Genes, jun Interleukin-2/GENETICS/METABOLISM Lymphocyte Transformation Mice Mice, Inbred C57BL Mice, Inbred DBA Mice, Knockout Mice, Transgenic Proto-Oncogene Proteins c-jun/GENETICS/*PHYSIOLOGY Receptors, Interleukin-2/METABOLISM Support, Non-U.S. Gov't Support, U.S. Gov't, P.H.S. T-Lymphocyte Subsets/*CYTOLOGY Thymus Gland/*CYTOLOGY/EMBRYOLOGY Transcription Factor AP-1/GENETICS/*METABOLISM Transcription Factors/METABOLISM
991230
A99C1076

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .